Close
Close
Finance News

CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX

3.0
3.0 from 3 votes
Thursday, January 18, 2018

SEATTLE - CTI BioPharma Corp. (NASDAQ and MTA:CTIC) announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with Teva under which CTI BioPharma is eligible to receive up to an additional $50 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.

About CTI BioPharma Corp.

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

Contacts:

Ed Bell
Phone: +1 206-272-4345
Email: ebell@ctibiopharma.com

Source: CTI BioPharma Corp.
3.0
3.0 from 3 votes
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
60 views
by Abidemi Uruejoma
78 views
by Abidemi Uruejoma
83 views